Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GoodRx Holdings Inc Market Cap
From what 15 stock analysts predict, the share price for GoodRx Holdings Inc (GDRX) might increase by 45.66% in the next year. This is based on a 12-month average estimation for GDRX. Price targets go from $4.5 to $10. The majority of stock analysts believe GDRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
GoodRx Holdings Inc has a total of 15 Wall St Analyst ratings. There are 8 buy ratings, 6 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that GoodRx Holdings Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GDRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Daniel Grosslight Citigroup | Buy | $7 | Maintains | Nov 13, 2024 |
| Stephanie Davis Barclays | Overweight | $6 | Maintains | Nov 11, 2024 |
| Sean Dodge RBC Capital | Outperform | $10 | Reiterates | Aug 16, 2024 |
| Kevin Caliendo UBS | Neutral | $8.5 | Maintains | Aug 9, 2024 |
| Daniel Grosslight Citigroup | Buy | $10 | Maintains | Aug 9, 2024 |
| Craig Hettenbach Morgan Stanley | Equal-Weight | $9.5 | Maintains | Jun 10, 2024 |
| Mark Mahaney RBC Capital | Outperform | $10 | Upgrade | May 23, 2024 |
| Stephanie Davis Barclays | Overweight | $10 | Maintains | May 20, 2024 |
| John Ransom Raymond James | Outperform | $10 | Upgrade | May 16, 2024 |
| Charles Rhyee TD Cowen | Buy | $16 | Maintains | May 16, 2024 |
| Scott Schoenhaus Keybanc | Overweight | $9 | Upgrade | Apr 10, 2024 |
| Stan Berenshteyn Wells Fargo | Overweight | $10 | Upgrade | Mar 25, 2024 |
| Sean Dodge RBC Capital | Sector Perform | $8 | Reiterates | Mar 8, 2024 |
| Eric Sheridan UBS | Neutral | $8 | Maintains | Mar 1, 2024 |
| Jailendra Singh Truist Securities | Hold | $8 | Maintains | Mar 1, 2024 |
| Eric Sheridan Goldman Sachs | Neutral | $7.5 | Maintains | Mar 1, 2024 |
| Stan Berenshteyn Wells Fargo | Equal-Weight | $7.5 | Maintains | Mar 1, 2024 |
| Charles Rhyee TD Cowen | Outperform | $14 | Maintains | Mar 1, 2024 |
| Steve Valiquette Barclays | Overweight | $9 | Maintains | Mar 1, 2024 |
| Sean Dodge RBC Capital | Sector Perform | $8 | Maintains | Mar 1, 2024 |
When did it IPO
2020
Staff Count
694
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Scott W. Wagner
Market Cap
$1.88B
In 2023, GDRX generated $750.3M in revenue, which was a decrease of -2.12% from the previous year. This can be seen as a signal that GDRX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - CNBC
Summary - Prescription fills for major weight loss drugs in the U.S. more than doubled in 2024, despite limited insurance coverage and high costs, according to GoodRx data.
Why It Matters - Rising prescription fills for weight loss drugs indicate strong consumer demand, potentially boosting revenues for companies like Novo Nordisk and Eli Lilly, impacting their stock performance positively.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GoodRx launched a Weight Loss Medications Tracker revealing ongoing strong demand for weight loss drugs like Mounjaro and Ozempic, despite limited insurance and high costs.
Why It Matters - GoodRx's new tracker reveals strong demand for weight loss medications despite high costs, indicating potential revenue growth in a lucrative market, which could positively impact the company's stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GoodRx Helps has awarded its 2024 Students for Healthcare Equity Scholarships to support underrepresented healthcare students, totaling $325,000 in grants to promote health equity.
Why It Matters - GoodRx's initiative to fund healthcare students from underrepresented groups may enhance its brand image and drive future growth, impacting its market position and investor confidence.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bragar Eagel & Squire is investigating potential claims against GoodRx Holdings (NASDAQ: GDRX) for possible fiduciary duty breaches by its board, following a class action filed on April 22, 2024.
Why It Matters - Potential legal issues and fiduciary duty breaches could lead to financial repercussions for GoodRx, impacting stock performance and shareholder value.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Kuehn Law is investigating GoodRx Holdings, Inc. (GDRX) for potential fiduciary duty breaches by insiders regarding misrepresentation of revenue reliance on Kroger.
Why It Matters - Allegations of fiduciary breaches and misleading representations can lead to legal liabilities and reputational damage for GoodRx, potentially impacting stock performance and investor confidence.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Harrow (Nasdaq: HROW) announced a new initiative to enhance access to its ophthalmic products, featuring price reductions and a partnership with GoodRx (Nasdaq: GDRX) for patient discounts.
Why It Matters - Harrow's initiative to reduce prices and partner with GoodRx enhances product accessibility, potentially increasing sales volume and market share, positively impacting revenue and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
